Vitamin D and osteoarthritis: evidence and interpretation

Note: This article was previously published and updated according to scientific and divulgative criteria. The text is for informational purposes only and does not replace the advice of a doctor.

IN BRIEF

• Associations exist between lower 25-OH-vitamin D levels and clinical or radiographic signs of osteoarthritis; observational associations do not prove causality.
• Randomized clinical trials on patients with knee osteoarthritis have yielded conflicting results: some small studies report improvements in pain, but larger RCTs have not shown consistent reduction in structural progression. [2][3][4][5]
• Recent meta-analyses summarize modest effects on pain and no clear effect on cartilage loss; doses and duration vary and can influence results. [6][7]
• Biological plausibility exists (vitamin D receptors in joint tissues, inflammatory modulation), but clinical data do not allow for generalized therapeutic recommendations without individual assessment. [8]

Abstract: what does science say?

Research has explored the role of vitamin D in maintaining joint health and its possible influence on the progression of osteoarthritis. Observational studies document that lower 25-OH-vitamin D levels often coexist with greater pain or signs of knee osteoarthritis progression, but they do not prove that deficiency is the primary cause of the disease. Controlled clinical trials, including two-year studies, have produced heterogeneous results: some pilot studies and controlled before/after studies found modest improvements in pain and function; larger and longer trials did not confirm a consistent effect on cartilage loss measured by imaging. Recent meta-analyses report small symptomatic improvements under specific conditions (e.g., daily doses greater than 2000 IU), with no robust effect on structural progression. In summary: biological plausibility is present, epidemiological associations are repeated, but experimental evidence does not support a clear conclusion: vitamin D can contribute to overall musculoskeletal health, but it is not proven as a definitive treatment for osteoarthritis. [Summary based on available evidence: see bibliography for verified DOI details]

MAIN SECTION

What we know from observational data

Numerous population and cohort studies have reported a correlation between low serum levels of 25-hydroxyvitamin D and a higher prevalence or intensity of joint pain, as well as, in some longitudinal studies, a higher probability of radiographic progression of knee osteoarthritis. It is important to note that these studies show associations: low vitamin D may be a marker of related conditions (age, sedentary lifestyle, obesity, less sun exposure) rather than a direct causal factor. Furthermore, the definition of "deficiency" varies among studies, with different cut-offs for 25-OH-D; this increases heterogeneity and complicates the interpretation of results. [1]

What clinical studies (controlled trials) say

Randomized trials have tested whether vitamin D supplementation can reduce pain or slow cartilage loss measured by MRI or X-ray. Two large controlled studies showed no significant effects on structural progression or WOMAC score in 1–2 year follow-up, while some smaller studies or pilot studies reported moderate improvements in pain or function. Differences in results depend on: inclusion criteria (patients with true deficiency vs. mixed populations), doses and administration schedule (monthly vs. daily), treatment duration, and outcome measures (symptoms vs. imaging). For this reason, RCTs currently do not provide uniform evidence to support the generalized prescription of vitamin D for osteoarthritis. [2][3][4][5]

What it means in practice

For the general public: maintaining adequate vitamin D levels is part of bone and muscle health care, especially in older people or those with risk factors for deficiency. However, specifically regarding the treatment or prevention of osteoarthritis, the evidence does not support the use of vitamin D supplementation alone as a proven strategy to stop cartilage loss or cure osteoarthritis. In practice, clinical evaluation should consider the overall picture: measured blood levels of 25-OH-vitamin D, presence of osteopenia/osteoporosis, personal risk factors, current medications, and patient preferences. In cases where a vitamin D deficiency is confirmed, correction according to bone health guidelines is appropriate and can have indirect benefits on muscle strength and joint function, elements that reduce the risk of falls and can improve quality of life. Avoid very high doses without medical supervision: excess can have risks (hypercalcemia, kidney damage). [1][5][6]

Typical clinical scenarios

If the doctor finds a documented deficiency (e.g., 25-OH-D below the recommended range), correction with targeted supplementation is justified for general bone and muscle health reasons and can be part of a multimodal strategy for patients with osteoarthritis (therapeutic exercise, weight control, physical therapy). If, on the other hand, the level is normal, current evidence does not justify preventive supplementation solely to slow osteoarthritis. In any case, decisions must be personalized and discussed with a healthcare professional. [2][6][7]

KEY POINTS TO REMEMBER

• Biological plausibility exists: vitamin D receptors and metabolic pathways in joint cells can influence inflammation and cartilage metabolism.
• Observational associations between low 25-OH-D levels and worse joint outcomes do not equate to proof of cause; confounding factors are frequent. [1]
• Large RCTs have not shown a clear structural benefit of supplementation, while smaller studies show conflicting results on pain and function. [2][3][4]
• Meta-analyses suggest modest symptomatic effects in particular dosages/subgroups, but no convincing effect on cartilage loss. [6][7]
• Documented correction of vitamin D deficiency remains indicated for general health; for osteoarthritis, the strategy must be integrated with non-pharmacological interventions and evaluated on a case-by-case basis. [5]

LIMITATIONS OF EVIDENCE

It is important to clearly distinguish between study types and methodological limitations. Observational studies can show associations but are susceptible to confounding and selection bias; they do not allow for causal inferences. Randomized trials offer a higher level of evidence, but many RCTs on the topic have limitations: insufficient sample sizes in some studies, heterogeneous inclusion criteria (initial deficit vs. normal levels), different formulations and dosing regimens, variable outcomes (subjective symptoms vs. structural measures with imaging), and often limited follow-up durations compared to the natural evolution of osteoarthritis. These elements reduce the generalizability of results and explain the variability of conclusions among studies and meta-analyses. [2][3][6]

Technical and contextual limitations

Vitamin D measurement can vary depending on the test used; "sufficiency" cut-offs are not universally agreed upon. Furthermore, osteoarthritis is a heterogeneous disease with complex mechanisms (mechanical, metabolic, inflammatory), and a single nutrient can hardly have an isolated definitive effect. Finally, the effect of supplementation may depend on dose, duration, and the patient's starting status (those who are clearly deficient may respond differently than those with adequate levels). [1][6][7]

Editorial conclusion

The relationship between vitamin D and osteoarthritis remains an evolving topic: research provides evidence of plausibility and association, but not consistent proof of the effectiveness of supplementation in stopping joint degeneration. For people with osteoarthritis, management should be multifactorial and based on interventions with established benefits (exercise, weight loss when indicated, physical therapy, pain control, comorbidity management). In the case of documented vitamin D deficiency, correction is appropriate and can improve muscle function and skeletal health, with relevant indirect benefits for those with joint problems. Any therapeutic choice must be discussed with the treating physician and adapted to the individual case.

Editorial note

This article has been updated to reflect the most recent scientific evidence available at the time of review. The purpose is informational: it does not provide medical prescriptions or replace a specialist visit. For therapeutic decisions, always consult your trusted doctor.

SCIENTIFIC RESEARCH

1. Muraki S, Dennison E, Jameson K, et al. Association of vitamin D status with knee pain and radiographic knee osteoarthritis. Osteoarthritis Cartilage. 2011;19(11):1301‑1308. https://doi.org/10.1016/j.joca.2011.07.017
2. McAlindon TE, LaValley MP, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA. 2013;309(2):155‑162. https://doi.org/10.1001/jama.2012.164487
3. Jin X, Jones G, Zhang W, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2016;315(10):1005‑1013. https://doi.org/10.1001/jama.2016.1961
4. Sanghi D, Mishra A, Sharma AC, et al. Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin Orthop Relat Res. 2013;471(11):3556‑3562. https://doi.org/10.1007/s11999-013-3201-6
5. Manoy P, Yuktanandana P, Tanavalee A, Anomasiri W, Ngarmukos S, Honsawek S. Vitamin D supplementation improves quality of life and physical performance in osteoarthritis patients. Nutrients. 2017;9(8):799. https://doi.org/10.3390/nu9080799
6. Gao X‑R, Chen Y‑S, Deng W. The effect of vitamin D supplementation on knee osteoarthritis: a meta‑analysis of randomized controlled trials. Int J Surg. 2017;46:14‑20. https://doi.org/10.1016/j.ijsu.2017.08.010
7. Wang R, Wang Z, Xiang S, et al. Relationship between 25‑hydroxy vitamin D and knee osteoarthritis: a systematic review and meta‑analysis of randomized controlled trials. Front Med (Lausanne). 2023;10:1200592. https://doi.org/10.3389/fmed.2023.1200592
8. Meta‑analysis: Vitamin D receptor (VDR) gene polymorphisms and osteoarthritis: systematic review and meta‑analysis. Rheumatology. 2021;60(2):538‑548. https://doi.org/10.1093/rheumatology/keaa644
9. Arden NK, Perry TA, et al. Effect of vitamin D therapy on synovial tissue volume and bone marrow lesions in symptomatic knee osteoarthritis: a randomized controlled trial. BMC Musculoskelet Disord. 2017/2019; (trial report). https://doi.org/10.1186/s12891-019-2424-4